Amneal Biosciences

RELUKO

Manufacturer:

Amneal Biosciences

Reluko HCPCS:

Q5125

HCPCS Code Descriptor:

Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram

Category:

Q Code

Reluko NDCs:

70121-1571-07, 70121-1569-07, 70121-1568-07, 70121-1570-07, 70121-1568-01, 70121-1570-01

Primary Type:

Oncology Biosimilar Colony Stimulating Factor

Generic/Specialty Status:

Single-Source

Package Type:

Multiple

Route of Administration:

Subcutaneous

Reluko CPT Codes:

Potential CPT administration codes for Reluko can be found at the following link.

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Reluko:

RELUKO is an Oncology Biosimilar Colony Stimulating Factor drug manufactured by Amneal Biosciences and administered via the Subcutaneous route of administration. The Q Code: Q5125 is aligned to the drug RELUKO.

Reluko is used to aid white blood cell production, acting as an artificial version of a substance the occurs naturally in the body. Reluko is administered via subcutaneous injection or intravenous infusion. Reluko is a branded drug manufactured by Amneal Pharmaceuticals. From July 2022 to September 2022, Reluko was assigned to the C Code: C9096. Since October 2022, Reluko has the Q code: Q5125. Reluko is a biosimilar for the reference drug Neupogen (J1442).

ACCESS PRICING AND MORE BY REGISTERING

Q5125 Added Date:

October 1, 2022

Q5125 Effective Date:

October 1, 2022

Q5125 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Reluko billing and coding information.
Our team did not identify a source for Reluko patient assistance information. Please reach out to our team if you feel that this is a mistake.
RELUKO prescribing information can be found at the link below:
Our team has not yet identified a source of side effects information for RELUKO. Please check back in a few weeks.